Nuveen LLC Takes $221,000 Position in Neumora Therapeutics, Inc. $NMRA

Key Points

• Nuveen LLC has acquired a new position in Neumora Therapeutics, purchasing 220,970 shares valued at approximately $221,000, bringing their total ownership to 0.14%.
• Other institutional investors, such as Lunate Capital Ltd and XTX Topco Ltd, also made significant investments in Neumora during the same quarter, indicating growing interest in the company.
• Neumora Therapeutics reported an EPS of ($0.33) for the last quarter, surpassing analysts' expectations, while the stock has a current average target price of $7.14.

Nuveen LLC acquired a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 220,970 shares of the company's stock, valued at approximately $221,000. Nuveen LLC owned 0.14% of Neumora Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Lunate Capital Ltd acquired a new position in shares of Neumora Therapeutics in the first quarter valued at approximately $2,124,000. XTX Topco Ltd boosted its holdings in shares of Neumora Therapeutics by 969.7% during the 1st quarter. XTX Topco Ltd now owns 233,597 shares of the company's stock worth $234,000 after buying an additional 211,759 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Neumora Therapeutics during the 1st quarter worth approximately $285,000. Ameriprise Financial Inc. bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $1,258,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Neumora Therapeutics by 793.5% during the 4th quarter. California State Teachers Retirement System now owns 54,457 shares of the company's stock worth $577,000 after buying an additional 48,362 shares in the last quarter. Institutional investors and hedge funds own 47.65% of the company's stock.

Analyst Upgrades and Downgrades

NMRA has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho lifted their price objective on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $7.14.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $1.68 on Friday. Neumora Therapeutics, Inc. has a twelve month low of $0.61 and a twelve month high of $17.19. The stock has a market cap of $272.08 million, a price-to-earnings ratio of -1.07 and a beta of 2.91. The business's fifty day moving average is $1.56 and its 200 day moving average is $1.15. The company has a quick ratio of 10.54, a current ratio of 10.54 and a debt-to-equity ratio of 0.11.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05. Research analysts expect that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.